Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Number of subjects with adverse events
研究概览
简要总结
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of GLPG1837 given to healthy subjects, compared to placebo. Also, the safety and tolerability of multiple ascending oral doses of GLPG1837 given to healthy subjects daily for 14 days compared to placebo, will be evaluated.
Furthermore, during the course of the study after single and multiple oral dose administrations, the amount of GLPG1837 and its metabolite present in the blood and urine (pharmacokinetics) will be characterized.
The effect of food on the pharmacokinetics of GLPG1837 and its metabolite will also be evaluated.
The potential of cytochrome P450 (CYP)3A4 induction after repeated dosing with GLPG1837 will be explored as well.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males or females of non-child bearing potential between 18-50 years of age (included)
- •Subjects must have a body mass index between 18-30 kg/m² (included)
- •Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram and laboratory findings
排除标准
- •A subject with a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
- •Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device or biologic investigational research study or participation within 15 weeks prior to initial study drug administration in an investigational research study with antibody administration
- •A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration
- •Current sexually active (and/or child wish) male; a contraception method should be used
- •Pregnant or lactating women or women of childbearing potential
研究组 & 干预措施
GLPG1837 single dose
Single oral dose of GLPG1837 suspension - ascending doses
干预措施: GLPG1837 single ascending doses (Drug)
Placebo single dose
Single oral dose of placebo suspension
干预措施: Placebo single dose (Drug)
GLPG1837 muliple doses
Multiple oral doses of GLPG1837 suspension - ascending doses
干预措施: GLPG1837 multiple ascending doses (Drug)
Placebo multiple doses
Multiple oral doses of placebo suspension
干预措施: Placebo multiple doses (Drug)
结局指标
主要结局
Number of subjects with adverse events
时间窗: Between screening and 7-10 days after the last dose
To evaluate the safety and tolerability of GLPG1837 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of adverse events
Number of subjects with abnormal laboratory parameters
时间窗: Between screening and 7-10 days after the last dose
To evaluate the safety and tolerability of GLPG1837 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal laboratory parameters
Number of subjects with abnormal vital signs
时间窗: Between screening and 7-10 days after the last dose
To evaluate the safety and tolerability of GLPG1837 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal vital signs
Number of subjects with abnormal electrocardiogram
时间窗: Between screening and 7-10 days after the last dose
To evaluate the safety and tolerability of GLPG1837 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal electrocardiograms
Number of subjects with abnormal physical examination
时间窗: Between screening and 7-10 days after the last dose
To evaluate the safety and tolerability of GLPG1837 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal physical examination
次要结局
- Ratio of 6-b-hydroxycortisol/cortisol in urine(Twelve hours before dosing on Day 1 and Day 14)
- The amount of GLPG1837 and its metabolite in plasma(Between Day 1 predose and 48 hours after the (last) dose)
- The amount of GLPG1837 and its metabolite in urine(Between Day 1 predose and 24 hours after the (last) dose)